IL17A and rheumatic disorder: Thus far, there has been no published data on utilizing secukinumab (currently the only IL-17 blocker having an indication in pediatric rheumatic disease) in the treatment of other pediatric rheumatic conditions than ERA and psoriatic arthritis.